New injection aims to help obese heart failure patients lose weight and feel better
NCT ID NCT06391710
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 study tests an injectable drug called HRS9531 in 203 obese adults with a type of heart failure where the heart pumps normally but is stiff. Participants receive either the drug or a placebo for 52 weeks. The main goals are to see if the drug helps with weight loss and improves heart-related quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HRS9531 injection
What this could lead to
If successful, this could point toward a new treatment option that helps obese people with heart failure lose weight and feel better day-to-day.
What could go wrong
This is an early Phase 2 trial with only 203 participants, so results may not apply to everyone. The drug may not improve heart failure outcomes or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH PRESERVED EJECTION FRACTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Anzhen Hospital, Capital Medical University
Beijing, Beijing Municipality, 100020, China